Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

NHS England appoints Sir James Mackey as CEO

Mackey is currently serving as chief executive of Newcastle Hospitals NHS Foundation Trust

- PMLiVE

DE&I in clinical trials: the role of health literacy and AI

By Claire Paling and Rosamund Round

- PMLiVE

FDA approves Mirum’s Ctexli as first treatment for rare lipid storage disease CTX

The progressive genetic disorder affects up to 2,000 people in the US

- PMLiVE

NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

- PMLiVE

Recce’s topical gel shows promise in acute bacterial skin and skin structure infections

ABSSSIs, including diabetic foot infections, are considered to be a significant healthcare concern

- PMLiVE

Porterhouse Medical appoints Michael Tague as president of Porterhouse Medical US

Tague most recently served as head of North America at CMC Connect

- PMLiVE

Class is the missing link in health equity strategies

By Jenny Carrington-Elson

- PMLiVE

Getting to know eLearning

At LOVELIVE we have a wealth of skills and experience when it comes to designing and producing engaging eLearning tools. User experience is key, so we combine easy to navigate...

LOVELIVE

- PMLiVE

PMLiVE’s Top Pharma list is live

The data was provided by GlobalData, a data analysis and consulting company

- PMLiVE

Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

Primary biliary cholangitis affects approximately 163,000 people in Europe

- PMLiVE

Standing out in a crowded precision oncology landscape

By Bea Mann

EU flag

EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links